ArticleMicroorganisms2021
Gut Dysbiosis and IL-21 Response in Patients with Severe COVID-19.
Article in Microorganisms, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 3 syntheses or guidelines pooled it, 56 citations in OpenAlex.
- Human microbiota dysbiosis after SARS-CoV-2 infection have the potential to predict disease prognosis.BMC infectious diseases · 2023Pooled it
- Meta-analysis of 16S rRNA microbial data identified alterations of the gut microbiota in COVID-19 patients during the acute and recovery phases.BMC microbiology · 2022Pooled it
- Diagnostic, Prognostic, and Therapeutic Roles of Gut Microbiota in COVID-19: A Comprehensive Systematic Review.Frontiers in cellular and infection microbiology · 2022Pooled it
- Impact of COVID-19 on the Gut Microbiome: A Review.Cureus · 2025Review
- Cytokine profiles dynamics in COVID-19 patients: a longitudinal analysis of disease severity and outcomes.Scientific reports · 2025Article
- Lung and gut microbiota profiling in intensive care unit patients: a prospective pilot study.BMC infectious diseases · 2025Observational
- Gut microbiota and viral respiratory infections: microbial alterations, immune modulation, and impact on disease severity: a narrative review.Frontiers in microbiology · 2025Review
- The Role of Gut Microbiota in the Modulation of Pulmonary Immune Response to Viral Infection Through the Gut-Lung Axis.Journal of inflammation research · 2025Review
- Microbiome dysbiosis in SARS-CoV-2 infection: implication for pathophysiology and management strategies of COVID-19.Frontiers in cellular and infection microbiology · 2025Review
- Diet-gut microbiome interaction and ferulic acid bioavailability: implications on neurodegenerative disorders.European journal of nutrition · 2024Review
- Gut Microbiome Disruption Following SARS-CoV-2: A Review.Microorganisms · 2024Review
- COVID-19 influenced gut dysbiosis, post-acute sequelae, immune regulation, and therapeutic regimens.Frontiers in cellular and infection microbiology · 2024Review
- The pediatric gut bacteriome and virome in response to SARS-CoV-2 infection.Frontiers in cellular and infection microbiology · 2024Article
- Temporal changes in fecal microbiota of patients infected with COVID-19: a longitudinal cohort.BMC infectious diseases · 2023Observational
- The F/B ratio as a biomarker for inflammation in COVID-19 and T2D: Impact of metformin.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2023Article
- Special Issue "Gastrointestinal Microbiota and Gut Barrier Impact Human Health and Disease": Editorial.Microorganisms · 2023Article
- Ecology and Machine Learning-Based Classification Models of Gut Microbiota and Inflammatory Markers May Evaluate the Effects of Probiotic Supplementation in Patients Recently Recovered from COVID-19.International journal of molecular sciences · 2023Article
- Intestinal barrier dysfunction as a key driver of severe COVID-19.World journal of virology · 2023Review
- Gut microbiota and COVID-19: A systematic review.Health science reports · 2023Article
- Development and management of gastrointestinal symptoms in long-term COVID-19.Frontiers in microbiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundThe disease severity, ranging from being asymptomatic to having acute illness, and associated inflammatory responses has suggested that alterations in the gut microbiota may play a crucial role in the development of chronic disorders due to COVID-19 infection. This study describes gut microbiota dysbiosis in COVID-19 patients and its implications relating to the disease.
designA cross sectional prospective study was performed on thirty RT-PCR-confirmed COVID-19 patients admitted to the All India Institute of Medical Sciences, Bhopal, India, between September 10 and 20, 2020. Ten healthy volunteers were recruited as the control group. IFN, TNF, and IL-21 profiling was conducted using plasma samples, and gut bacterial analysis was performed after obtaining the metagenomics data of stool samples.
resultsPatients with a variable COVID-19 severity showed distinct gut microflora and peripheral interleukin-21 levels. A low Firmicute/Bacteroidetes ratio, caused by the depletion of the fibre-utilizing bacteria,
conclusionsThe loss of the functional attributes of signature commensals in the gut, due to dysbiosis, is a predisposing factor of COVID-19 pathophysiology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.